Tonix Pharmaceuticals Holding CorpNASDAQ:TNXP
- LAST PRICE0.7199
- TODAY'S CHANGE (%)-0.0174 (-2.3600%)
- Bid / Lots0.7051/ 6
- Ask / Lots0.7200/ 1
- Open / Previous Close0.7550 / 0.7373
- Day Range
- 52 Week Range
- Volume350,962
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TNXP |
|---|---|---|
| 09:32 ET | 1659 | 0.755 |
| 09:34 ET | 350 | 0.753469 |
| 09:38 ET | 1000 | 0.755 |
| 09:39 ET | 347 | 0.745247 |
| 09:41 ET | 300 | 0.74 |
| 09:45 ET | 1000 | 0.7415 |
| 09:54 ET | 26232 | 0.7201 |
| 09:57 ET | 100 | 0.721 |
| 09:59 ET | 2054 | 0.73 |
| 10:01 ET | 2400 | 0.725049 |
| 10:03 ET | 1238 | 0.729899 |
| 10:06 ET | 300 | 0.7293 |
| 10:08 ET | 1250 | 0.73 |
| 10:10 ET | 100 | 0.725 |
| 10:12 ET | 30746 | 0.7 |
| 10:14 ET | 7467 | 0.7 |
| 10:15 ET | 1638 | 0.72 |
| 10:17 ET | 6733 | 0.72 |
| 10:19 ET | 14384 | 0.72 |
| 10:21 ET | 7100 | 0.7201 |
| 10:26 ET | 11198 | 0.7201 |
| 10:32 ET | 3097 | 0.7201 |
| 10:33 ET | 100 | 0.72005 |
| 10:39 ET | 9769 | 0.72 |
| 10:44 ET | 2194 | 0.711355 |
| 10:46 ET | 1000 | 0.72 |
| 10:50 ET | 129 | 0.72 |
| 10:57 ET | 31000 | 0.72 |
| 11:00 ET | 100 | 0.72 |
| 11:02 ET | 1000 | 0.72 |
| 11:08 ET | 200 | 0.717999 |
| 11:11 ET | 10000 | 0.716 |
| 11:18 ET | 1208 | 0.7199 |
| 11:20 ET | 232 | 0.7199 |
| 11:22 ET | 10300 | 0.72 |
| 11:24 ET | 138 | 0.72 |
| 11:33 ET | 3699 | 0.72 |
| 11:36 ET | 400 | 0.72 |
| 11:40 ET | 10150 | 0.7186 |
| 11:44 ET | 200 | 0.72 |
| 11:45 ET | 19113 | 0.72 |
| 11:47 ET | 7206 | 0.7 |
| 11:51 ET | 1730 | 0.7 |
| 11:54 ET | 1800 | 0.6922 |
| 11:56 ET | 9868 | 0.7 |
| 11:58 ET | 70103 | 0.72 |
| 12:02 ET | 7986 | 0.72 |
| 12:03 ET | 4302 | 0.7117 |
| 12:05 ET | 1000 | 0.7199 |
| 12:07 ET | 1000 | 0.7003 |
| 12:09 ET | 543 | 0.7101 |
| 12:25 ET | 200 | 0.72 |
| 12:30 ET | 400 | 0.716086 |
| 01:01 ET | 1698 | 0.71 |
| 01:03 ET | 200 | 0.71 |
| 01:06 ET | 400 | 0.71 |
| 01:08 ET | 121 | 0.700542 |
| 01:14 ET | 250 | 0.7099 |
| 01:15 ET | 1100 | 0.702 |
| 01:17 ET | 1900 | 0.71 |
| 01:30 ET | 1800 | 0.7199 |
| 02:00 ET | 180 | 0.7137 |
| 02:02 ET | 100 | 0.719999 |
| 02:08 ET | 650 | 0.7199 |
Yesterday
Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina's Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder, from 8:30AM ET on Wednesday Sep 27, 2023 by Dow Jones
8:30AM ET on Wednesday Sep 27, 2023 by Dow Jones
Sep 21, 2023
Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023, from 7:00AM ET on Thursday Sep 21, 2023 by Dow Jones
7:00AM ET on Thursday Sep 21, 2023 by Dow Jones
Sep 18, 2023
Sep 15, 2023
Sep 14, 2023
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tonix Pharmaceuticals Holding Corp | 13.1M | -0.1x | --- |
Dominari Holdings Inc | 12.8M | -0.5x | --- |
Eloxx Pharmaceuticals Inc | 13.8M | -0.4x | --- |
GeoVax Labs Inc | 13.5M | -0.7x | --- |
Weed Inc | 12.3M | -7.2x | --- |
Frequency Therapeutics Inc | 14.1M | -0.2x | --- |
Company Information
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg. Its portfolio consists of central nervous system (CNS), rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases and cancer. Its infectious disease portfolio includes a vaccine in development to prevent smallpox and mpox, vaccines to prevent COVID-19, a platform to make fully human monoclonal antibodies (mAbs), to treat COVID-19 and humanized anti-SARS-CoV-2 mAbs. Its product candidates include TNX-102 SL, TNX-4300, TNX-1900, TNX-601 ER and others.
Contact Information
- Headquarters
- 26 Main Street, Suite 101CHATHAM, NJ, United States 07928
- Phone
- 212-980-9155
- Fax
- 212-923-5700
Executives
- Chairman of the Board, President, Chief Executive Officer
- Seth Lederman
- Chief Financial Officer, Treasurer
- Bradley Saenger
- Chief Operating Officer
- Jessica Morris
- Executive Vice President - Medical
- Zeil Rosenberg
- Secretary, Chief Medical Officer
- Gregory Sullivan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 17.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.21 |
EPS | $-13.70 |
Book Value | $16.93 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
